The first quarter is a wrap and Abbott is off to a very good start with strong growth across all four of the company's major businesses. This growth translated to worldwide sales for the quarter of $10.5 billion, up 32.9% on an organic basis (35.3% reported), excluding the impact of foreign exchange. Abbott's ongoing earnings per share was $1.32, reflecting 103.1% growth compared to the prior year.1 While Diagnostics led Abbott's growth, driven by the company's robust portfolio of COVID-19 tests, that’s only part of the story. This quarter also saw strong growth in Adult Nutrition, Medical Devices — led by Diabetes Care and Structural Heart — as well as increasing demand for other instruments and routine tests in Abbott's Core Lab business. Given this strong quarter, Abbott is on track with its expectations for the year and well-positioned to deliver on its 2021 guidance, reflecting another year of impressive performance. These are some of the key first-quarter highlights: Strong Medical Device sales, up 8.8% organic (13.1% reported), were driven by continued recovery from the COVID-19 pandemic. Leading this growth for the quarter was Diabetes Care, with $829 million in sales of Abbott's FreeStyle Libre system and Libre Sense. The FreeStyle Libre system now has more than 3 million users worldwide.2 Significant growth in Diagnostics, 114.8% organic (119.8% reported), was once again driven by demand for Abbott’s robust and global portfolio of rapid and lab-based COVID-19 diagnostics tests, which can be used in a variety of settings. The latest is Abbott's rapid antigen BinaxNOW COVID-19 Self Test, an over-the-counter test for people with or without symptoms, which is shipping to retailers across the U.S. this week. The test received emergency use authorization (EUA) in April from the U.S. Food and Drug Administration (FDA). Overall, Abbott has provided nearly 700 million COVID-19 diagnostics tests since the start of the pandemic. Excluding COVID-19 sales, Core Lab and Molecular Diagnostics sales had double-digit growth on an organic basis in the quarter.3 Strong Nutrition growth, of 6.4% organic (6.9% reported) was spurred by demand for Abbott's Adult Nutrition products, which had double-digit growth led by Ensure, Abbott’s market-leading nutrition brand and Glucerna, Abbott’s best-in-class diabetes nutrition product. New approvals in the quarter have added more momentum to Abbott’s already strong portfolio of life-changing technologies. This includes two first-of-their-kind innovations with Abbott receiving FDA clearance for its i-STAT Alinity TBI plasma test* (the first rapid handheld objective blood test for traumatic brain injury) and FDA approval of NeuroSphere Virtual Clinic (a first-of-its-kind technology allowing patients with chronic pain or movement disorders to receive new treatment settings remotely). Abbott also received EUA from the FDA in March for its Alinity m Resp-4-Plex test, allowing healthcare workers to detect four respiratory viruses (influenza types A and B, RSV and COVID-19) with just one swab. And in April, Abbott announced CE Mark for its next-generation TriClip device,** a minimally invasive therapy providing a new treatment option for a common heart valve issue. For full financials and reconciliation of non-GAAP measures, you can read Abbott's press release. For further information, take a look at some additional materials below: Abbott President and CEO Robert Ford shares his thoughts on the continued importance of rapid COVID-19 tests.